Everence Capital Management Inc. Has $3.68 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Everence Capital Management Inc. lessened its position in Amgen Inc. (NASDAQ:AMGNFree Report) by 6.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,120 shares of the medical research company’s stock after selling 920 shares during the period. Everence Capital Management Inc.’s holdings in Amgen were worth $3,680,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. Ascent Group LLC grew its position in Amgen by 0.3% during the second quarter. Ascent Group LLC now owns 10,949 shares of the medical research company’s stock worth $3,421,000 after buying an additional 31 shares in the last quarter. Cadinha & Co. LLC grew its holdings in shares of Amgen by 0.6% during the third quarter. Cadinha & Co. LLC now owns 5,209 shares of the medical research company’s stock worth $1,678,000 after purchasing an additional 32 shares in the last quarter. Lansing Street Advisors increased its position in shares of Amgen by 1.3% in the third quarter. Lansing Street Advisors now owns 2,582 shares of the medical research company’s stock worth $832,000 after purchasing an additional 32 shares during the last quarter. Unionview LLC raised its stake in Amgen by 3.8% in the third quarter. Unionview LLC now owns 876 shares of the medical research company’s stock valued at $282,000 after purchasing an additional 32 shares in the last quarter. Finally, D Orazio & Associates Inc. lifted its position in Amgen by 1.1% during the second quarter. D Orazio & Associates Inc. now owns 3,101 shares of the medical research company’s stock valued at $969,000 after purchasing an additional 33 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.4 %

Amgen stock traded up $1.10 during mid-day trading on Friday, reaching $260.38. 472,873 shares of the company traded hands, compared to its average volume of 1,398,615. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The firm has a market capitalization of $139.96 billion, a price-to-earnings ratio of 33.34, a P/E/G ratio of 2.91 and a beta of 0.55. The firm’s 50 day moving average price is $285.75 and its 200 day moving average price is $310.70.

Amgen (NASDAQ:AMGNGet Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the previous year, the company earned $4.96 earnings per share. Amgen’s quarterly revenue was up 23.2% on a year-over-year basis. On average, analysts anticipate that Amgen Inc. will post 19.53 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.66%. The ex-dividend date is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is presently 121.90%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AMGN. Wolfe Research initiated coverage on shares of Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Leerink Partners reduced their price objective on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. TD Cowen boosted their target price on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Royal Bank of Canada reduced their price target on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 27th. Finally, Robert W. Baird restated an “underperform” rating and issued a $215.00 price objective on shares of Amgen in a report on Wednesday, September 25th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $318.83.

Get Our Latest Stock Analysis on Amgen

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Recommended Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.